Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMOZIDE vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Prazosin is extensively metabolized in the liver via demethylation and conjugation. Polythiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Approximately 85-90% bound to serum albumin and alpha-1 acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
0.5-0.8 L/kg, indicating moderate distribution into extravascular tissues. Clinically, this suggests loading doses may be needed for rapid effect.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral bioavailability is 40-60% due to first-pass metabolism. Intravenous bioavailability is 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 5 mg once daily. GFR 15-29 m L/min: 2.5 mg once daily. GFR <15 m L/min: Not recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not approved for pediatric use. Safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and renal impairment risk.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Orthostatic hypotension and syncope, especially with first dose,Sodium and fluid depletion,Electrolyte imbalances (hypokalemia, hyponatremia),Renal impairment,Hepatic impairment,Possible increased risk of adverse effects in patients on beta-blockers or digitalis
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to prazosin, polythiazide, or sulfonamides,Anuria,Hepatic coma or precoma,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, avocados) and potassium-containing salt substitutes. Grapefruit may increase drug levels; avoid grapefruit juice.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: Increased risk of fetal renal dysfunction, oligohydramnios, and neonatal complications such as hypotension, hyperkalemia, and skull hypoplasia.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
NORMOZIDE is excreted in breast milk. M/P ratio: approximately 0.8. Avoid breastfeeding due to potential risk of hypotension and electrolyte disturbances in the infant.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
NORMOZIDE is not recommended in pregnancy. If used inadvertently, dose adjustments are not indicated; immediate discontinuation advised. Plasma levels may decrease in pregnancy due to increased volume of distribution, but no safe dosage can be established.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Monitor serum potassium and renal function before and during therapy due to risk of hyperkalemia. Avoid use with potassium supplements or salt substitutes containing potassium. Adjust dose in elderly and patients with hepatic impairment. Caution in patients with severe renal impairment (Cr Cl <30 m L/min).
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily.,Avoid potassium-rich foods and salt substitutes.,Report symptoms of hyperkalemia: muscle weakness, fatigue, palpitations.,May cause dizziness; avoid driving until effect known.,Do not stop abruptly without consulting prescriber.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMOZIDE vs ALDORIL D30, answered by our medical review team.
NORMOZIDE is a Antihypertensive Combination that works by Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMOZIDE and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMOZIDE is: Oral: 10 mg once daily. Maximum dose: 20 mg once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMOZIDE and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMOZIDE is classified as Category C. NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Seco. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.